Accordingly, targeting the ROS-TXNIP-NLRP3 pathway has been proposed as a therapeutic opportunity for preventing the progression of NAFLD to NASH in DM [185]. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.